In clinical study, NSCLC patients whose tumoural PD-L1 expression exceeded 50% had a higher response rate to anti-PD-1, prolonged progression free survival and overall survival than those with low PD-L1 expressing tumours [13,38]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.